Cancer Genetics Inc

Cancer Genetics — Investor Presentation (September 2013)

36 slides from Cancer Genetics's investor presentation, Sep 20, 2013

  1. Slide 1: Empowering Personalized Cancer Treatment

    Exhibit 99.1 EMPOWERING PERSONALIZED CANCER TREATMENT CGIX September 19, 2013 (NASDAQ)

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Cancer Genetics, Inc. (The Company) products and services, along with other statements about the future expec

  3. Slide 3: Growth-Stage, Oncology-Focused, Personalized-Diagnostics Company

    Growth-Stage, Oncology-Focused, Personalized-Diagnostics Company Established multi-year track record of top-line growth with improving margins Hybrid business model providing proprietary genomic products, clinical cancer testing and clinical trial services for biotechs and pharmas Portfolio of comme

  4. Slide 4: Molecular Diagnostics are Changing our Understanding of Cancer

    Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients Our unique focus & approach supports the entire cancer care continuum DIAGNOSIS PROGNOSIS THERANOSIS Use genomics to Assist in patient Personalize provide an accurate outcome and dis

  5. Slide 5: CGI's Mission is to Personalize and Improve the Success Rate in Cancer Treatment

    CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment Traditional Approach Our Approach: Personalized Medicine Phenotypic & Biomarkers and Physical Examination Companion Diagnostics Morphologic & Genomic Analysis & Pathological Analysis Proprietary Algorithms Large & Multi

  6. Slide 6: Unique, Scalable and Multifaceted Business Model

    Unique, Scalable and Multifaceted Business Model PROPRIETARY PRODUCTS CLINICAL SERVICES BIOPHARMA PARTNERSHIPS Proprietary molecular Differentiated and complete Biomarker and companion diagnostics & FISH probes disease-focused solutions diagnostic development Clinically validated Superior turnaround

  7. Slide 7: Our Target Markets in Oncology Testing Comprise Over 610,000 New Lives Annually in the U.S.

    Our Target Markets in Oncology Testing Comprise Over 610,000 New Lives Annually in the U.S. Hematological: Urogenital: Gynecological: Lymphoma, Leukemia, M. Myeloma Kidney, Bladder & Prostate Cervical, Endometrial & Ovarian 149,990 376,310 84,140 2013 Estimated New Cases 2013 Estimated New Cases 201

  8. Slide 8: 5 Proprietary Diagnostic Products Commercially Launched & In Market

    5 Proprietary Diagnostic Products Commercially Launched & In Market Research & Clinical Commercial Launch & Clinical Collaboration & Discovery Development Development Market Entry Validation Partners MatBA® - Chronic & Small Lymphocytic Leukemia MatBA® - Diffuse Large B-Cell Lymphoma MatBA® - Mantle

  9. Slide 9: Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising

    Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs (US Only, per 100,000) 21.2 89 20.0 19.7 20.5 18.5 15.5 12.6 11.1 8.7 8.2 12 7.1 7.9 6.9 7.3 1 2 5 5.6 6.2 100 80 60 30 2 1975 1985 1995 200

  10. Slide 10: MatBA-CLL/SLL Array-CGH Improves Risk Stratification & Outcome Prediction

    MatBA®-CLL/SLL Array-CGH Improves Risk Stratification & Outcome Prediction Impact on therapy selection & FISH clinical management of CLL (Current Method) (CGI Method) patients. Favorable 38% of cases in our study have Intermediate 38% a favorable prognosis falling Unfavorable under "watch & wait" ap

  11. Slide 11: MatBA Can Group Patients Into Risk Groups and Prognostication Classes

    MatBA®Can Group Patients Into Risk Groups and Prognostication Classes MatBA®- CLL / SLL is a diagnostic tool and Time to First Treatment (TTFT) prognostic indicator for patient stratification and improved patient management Being actively used in clinical care, in clinical trials and in validation p

  12. Slide 12: UroGenRA-Kidney Can Help Decide if Partial Kidney Removal Is Required

    UroGenRA™-Kidney Can Help Decide if Partial Kidney Removal Is Required and Guide Treatment Selection PROBLEM SOLUTION Men and women with renal masses UroGenRA™ is designed to detect genomic often undergo unnecessary aberrations in a single assay in percutaneous nephrectomy for accurate diagnosis nee

  13. Slide 13: FHACT - A New Genomic Aid In The Screening & Management Of Cervical Cancer

    FHACT™- A New Genomic Aid In The Screening & Management Of Cervical Cancer Cervical cancer effects nearly 500,000 women annually with nearly 80% in developing countries. HPV+ 90% Regress Abnormal 10% Progress to Normal Grade Cervical to Higher Grade Decreased Risk for Cancer Lesions Increased Risk f

  14. Slide 14: IP Position and Detailed Global Strategy

    IP Position and Detailed Global Strategy Panel for the Detection and Differentiation of Renal Tool for Diagnosis and Prognosis of Mature B-Cell Cortical Neoplasms Neoplasms US 11/932,422 US 12/980,480 Europe 08844570.5 US 13/475,034 Europe 10803548.6 Methods of Analyzing Chromosomal Translocations I

  15. Slide 15: Large, Targeted Market Opportunities with Extensive Value Creation for Key Markets

    Large, Targeted Market Opportunities with Extensive Value Creation for Key Markets Target Markets Commercialization Strategy Collaborate to create and validate microarrays Universities and Research Centers and other proprietary products Accelerate launch of large scale studies Continue to growing sa

  16. Slide 16: Unique Service Offering Developed to Enable Community Hospitals

    Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally Delivers better outcomes to community hospitals and Expanding & Developing Cancer Care laboratories is a Top Priority for Hospital CEOs & CFOs Enables community hospitals to bring “sta

  17. Slide 17: Clinical Trial Services Showing Strong Growth and Robust Pipeline

    Clinical Trial Services Showing Strong Growth and Robust Pipeline ONCOLOGY DRUGS ASSOCIATED GROWTH IN CGI’s DIRECT BILL WITH BIOMARKER(S) CLIENTS ($000) $1,738 55% $684 21% $221 2011 2016 1H, 2011 1H, 2012 1H, 2013 Source: Company Analysis and Management Estimates Well-Positioned for Use in Clinical

  18. Slide 18: Gilead is Currently Using a Comprehensive Panel of CGI Services

    Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for Hematologic Cancers Highlights Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring Improved patient profiling will result i

  19. Slide 19: Collaborations with Premier Cancer Research Institutions

    Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption Research Collaboration/ Clinical Partnership Licensing Services Highlights Renal Cancer, DLBCL, MCL & FL Joint Venture Focused on Oncology & Next Generation Sequencing Cervical Cancer

  20. Slide 20: Well-Positioned and Growing Internationally Including in Emerging Economies

    Well-Positioned and Growing Internationally Including in Emerging Economies International revenue comes from sale of oncology products (DNA-FISH probes, arrays) and services to emerging economies Expect exposure to increase to emerging economies through strong partnerships with Kamineni Life Science

  21. Slide 21: Roche Partnership

    Roche Partnership Expanding Market Presence Internationally CGI will be providing genomic and biomarker testing services to 14 countries in Central America and The Caribbean. Highlights CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin America) Roch

  22. Slide 22: Mayo Clinic Joint Venture

    Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics Next Generation Sequencing in Oncology Highlights JV to develop clinical diagnostic products and services on NGS platform(s) for select cancers Select three initial projects in key oncology categories by the SRC (Scientific Revie

  23. Slide 23: Strong History of Growth Trailing 12 Months Revenue is $5.4 Mn

    Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013thru 6 mos) Total Revenue ($Mn) Clinical Volume (Tests Processed) 6,610 $4.30 5,115 $3.02 $3.05 $2.52 3,622 3,146 $1.67 2,321 2009 2010 2011 2012 1H-2013 2009 2010 2011 2012 1H-2013 Trailing 12 Months Revenue is $5.4 Mn 2013 C

  24. Slide 24: Strong History of Growth - Revenue & Clinical Volume Trends

    Strong History of Growth - Revenue & Clinical Volume Trends (Quarterly Comparison 2012 vs. 2013) Total Revenue ($000) Clinical Volume (Tests Processed) $1,832 3,204 60% 97% 46% 19% $1,218 $1,148 1,911 1,610 1,623 $835 Grants* Grants* 2012 2013 2012 2013 2012 2013 2012 2013 st nd st nd 1 Quarter 2 Qu

  25. Slide 25: Summary Statement of Operations

    Summary Statement of Operations (2009-2013 thru 6 mos) Income Statement Item 2009 2010 2011 2012 1H-2013 Revenue $1,666 $2,522 $3,019 $4,302 $3,050 Gross Profit (866) (995) (98) 373 701 Gross Margin (%) (52%) (39%) (3%) 9% 23% Research & Development (R&D) 1,336 1,167 2,074 2,112 951 Sales & Marketin

  26. Slide 26: Summary Statement of Operations

    Summary Statement of Operations (Quarterly & First Half Comparisons 2012 vs. 2013) Income Statement Item Q2 2012 Q2 2013 % 1H 2012 1H 2013 % Revenue $1,148 $1,832 60% $1,983 $3,050 54% Gross Profit 62 553 +100% 74 701 +100% Gross Margin (%) 5% 30% +100% 4% 23% +100% Research & Development (R&D) 527

  27. Slide 27: Summary Balance Sheet

    Summary Balance Sheet Actual 06/30/13 Pro Forma (A) Cash & Cash Equivalents $1,941 $12,933 Total Assets 6,456 17,303 Total Liabilities 13,325 9,681 Stockholders’ (Deficit) Equity (6,869) 7,622 $ in thousands (A) Pro Forma basis gives effect to (i) the receipt of net proceeds of approximately $13.5 M

  28. Slide 28: Consistent Focus on Gross Profit Improvements

    Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India Gross Profit Margin Highlights of Initiatives 800 Manufacturing in India (Probes) 600 23% Increased automation 400 9% Process improvement and 200 innovation 0 (3%) Capacity utilization (52%) (39%) 20

  29. Slide 29: Multiple Customer Types Provide Diversified Revenue Mix

    Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place Payor Revenue Mix 2013 (1H, 2013) Selected Payors 57 million covered lives through multiple payors: 1H, 2013 Direct Bill Customer Types Academic Biotechs Cancer Facilities Reimbursement Based Direct Bill / Pa

  30. Slide 30: Experienced and Focused Management and Boards

    Experienced and Focused Management and Boards Board of Directors Raju Chaganti, Ph.D. | Keith Brownlie | John Pappajohn | Franklyn Prendergast, M.D., Ph.D. Panna Sharma | Edmund Cannon | Andrew Pecora, M.D. | The Honorable Tommy G. Thompson Officers & Management Team Scientific Advisory Board Andrea

  31. Slide 31: Strong, Commercially-Focused News Flow & Consistent Achievement of Milestones

    Strong, Commercially-Focused News Flow & Consistent Achievement of Milestones Expected in Coming Quarters Recent Accomplishments Upcoming Milestones & Value Drivers Accelerating market traction – over 50% quarter to quarter growth in 2013 Increasing covered lives market access through additional and

  32. Slide 32: Contact Cancer Genetics, Inc.

    For further information, please contact us at [email protected] Cancer Genetics, Inc. Meadows Office Complex 201 Route 17 North Rutherford, NJ 07070 (201) 528-9200 www.cancergenetics.com

  33. Slide 33: Appendix

    Appendix

  34. Slide 34: MatBA-CLL/SLL Delivers Clear Value in Personalization of Leukemia Treatment

    MatBA®-CLL/SLL Delivers Clear Value in Personalization of Leukemia Treatment – Clinical Case Study CASE #174 FISH favorable/intermediate Contradictory Prognoses Conflicting outcome (13q loss) Left a Key Question: How to Previous Molecular poor outcome Best Manage & Treat This Prognoses (IGHV status:

  35. Slide 35: FHACT Fits Directly into Today's Cervical Cancer Screening Workflow

    FHACT™Fits Directly into Today’s Cervical Cancer Screening Workflow as Additional Triage – Clinical Case Study CASE #021 Low grade cervical lesions may Will The Patient’s Low- Pap Smear regress (~90%) or progress (~10%) Grade Cervical Lesion Classified as Patients are typically referred for Progress

  36. Slide 36: Expanding Proprietary Capabilities Across Full Range of DNA Detection Methodologies

    Expanding Proprietary Capabilities Across Full Range of DNA Detection Methodologies DNA-FISH Probe Low Resolution (~1-2Mb) Mid-High Market Maturity Value: High in established markets and growing in emerging markets Existing CGI Capabilities DNA Microarray High Resolution (~1-2kb) Low-Mid Market Matu

Cancer Genetics — Investor Presentation (September 2013) on 6ix